Scientists Say They ’ve Reached Turning Point in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine.
After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years.
These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer.
More from TIME
[video id=W5jcvwLu autostart="viewable"]
“We’re getting something to work. Now we need to get...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news
Might Hepatitis D Virus Cause More Diseases Than Initially Thought?
Hepatitis D virus depends on a helper virus to enter host cells. Hepatitis B virus was long considered its sole helper. Novel research suggests otherwise. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 16, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Roche awarded WHO prequalification for the cobas ® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries
Every year, over 600,000 women worldwideare diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women who die from cervical cancer live in low- and lower-middle income countries (LMICs).1WHO prequalification enables LMICs to use thecobas® HPV test in their national cervical cancer elimination programs, increasing access to the patients who need it most.Establishing screening programs helps prevent and detect cervical cancer, which is especially important in areas with limited healthcare resources where patientsare often diag...
Source: Roche Media News - June 13, 2023 Category: Pharmaceuticals Source Type: news
Roche awarded WHO prequalification for the cobas ® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries
Every year, over 600,000 women worldwideare diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women who die from cervical cancer live in low- and lower-middle income countries (LMICs).1WHO prequalification enables LMICs to use thecobas® HPV test in their national cervical cancer elimination programs, increasing access to the patients who need it most.Establishing screening programs helps prevent and detect cervical cancer, which is especially important in areas with limited healthcare resources where patientsare often diag...
Source: Roche Investor Update - June 13, 2023 Category: Pharmaceuticals Source Type: news
Nigeria: Hepatitis B Is a Life-Threatening Liver Infection - Our Machine Learning Tool Could Help With Early Detection
[The Conversation Africa] More than 296 million people worldwide live with hepatitis B, a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Most don't know they are infected, so they don't get medical care. Clinical care improves the patient's outcome and can prevent them from infecting others. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 6, 2023 Category: African Health Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Africa: High-Level Resource Mobilization Conference to Eliminate Viral Hepatitis
[WHO] The Hepatitis Fund and the Clinton Health Access Initiative (CHAI) will partner on the inaugural Global Hepatitis Resource Mobilization Conference taking place in Geneva on 17 May 2023. The high-level conference will be hosted by the Arab Republic of Egypt and the Kingdom of Saudi Arabia, 2 countries with high burdens of hepatitis C and hepatitis B respectively. The event is a global call to action to boost financial and political commitment towards viral hepatitis elimination by 2030. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 18, 2023 Category: African Health Source Type: news
Arbutus Biopharma shares decline as FDA puts hold on drug study application
The Bucks County company's investigational new drug application is for an experimental therapy to treat hepatitis B infections. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 26, 2023 Category: American Health Authors: John George Source Type: news
Africa: 'Vaccinate Against Deadly Diseases Including Covid-19'
[ADAPT] African Vaccination Week is a crucial reminder of the life-saving power of vaccines. From COVID-19 to polio, diphtheria, tetanus, hepatitis B, influenza, rotavirus, measles, and the human papillomavirus (HPV), vaccines offer protection against deadly diseases. With this week falling on the last week of April, there is no better time to prioritize vaccination. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 25, 2023 Category: African Health Source Type: news
ACIP 2023 Recommended Immunization Schedule for Adults ACIP 2023 Recommended Immunization Schedule for Adults
Review vaccine-specific changes in the 2023 immunization schedule for adults aged 19 years and older, including updates to influenza, hepatitis B, and pneumococcal vaccination.Morbidity & Mortality Weekly Report (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 24, 2023 Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news
Dried Blood Spot Test Validated for HIV, Hep B, and Hep C Dried Blood Spot Test Validated for HIV, Hep B, and Hep C
A test for HIV, hepatitis B, and hepatitis C that uses a single dried blood spot could increase testing for these viruses in high-risk and challenging settings, new data show.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 19, 2023 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
Racial Disparities Not Found in Hepatitis B Treatment Initiation Racial Disparities Not Found in Hepatitis B Treatment Initiation
When researchers compared patients who met treatment criteria, treatment initiation was similar across races and socioeconomic status. But that finding raises other questions.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 11, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Black Patients Less Likely to Meet Hep B Treatment Criteria
(MedPage Today) -- While Black patients with chronic hepatitis B virus (HBV) infection were less likely to meet treatment criteria, race and socioeconomic factors were not associated with treatment initiation, a longitudinal observational study... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 10, 2023 Category: American Health Source Type: news
